Skip to main content

Table 2 Multivariate analysis for PSA-PFS

From: Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL

  Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
 ≥ 75 years old at diagnosis 1.09 0.55–2.16 0.79 1.17 0.59–2.35 0.65
CAB therapy with GnRH antagonist 0.40 0.16–0.87 0.02 0.41 0.16–0.90 0.03
Bone metastasis positive 4.12 1.93–9.79 < 0.01 3.60 1.66–8.74 < 0.01
Gleason score ≥ 8 3.38 1.21–14.07 0.02 1.94 0.66–8.34 0.25
  1. CAB combined androgen blockade, CI confidential interval, HR hazard ratio, PFS progression-free survival, PSA prostate-specific antigen